NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RNXT

RenovoRx Inc

Jul 03 • 04:00PM ET

1.36

Dollar change +0.06
Percentage change 4.62	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP ALNY NTLA ARWR EDIT FATE ADVM BLUE CLLS

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.40	Insider Own	3.42%	Shs Outstand	36.55M	Perf Week	0.74%
Market Cap	49.74M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	15.11%	Shs Float	35.32M	Perf Month	-0.73%
Enterprise Value	35.44M	PEG	-	EPS next Q	-0.09	Inst Own	27.55%	Short Float	0.39%	Perf Quarter	36.00%
Income	-10.16M	P/S	207.25	EPS this Y	18.75%	Inst Trans	9.06%	Short Ratio	0.83	Perf Half Y	-2.16%
Sales	0.24M	P/B	3.78	EPS next Y	-1.54%	ROA	-97.66%	Short Interest	0.14M	Perf YTD	5.43%
Book/sh	0.36	P/C	3.41	EPS next 5Y	-	ROE	-136.13%	52W High	1.69 -19.52%	Perf Year	18.26%
Cash/sh	0.40	P/FCF	-	EPS past 3/5Y	17.62% 2.24%	ROIC	-76.13%	52W Low	0.75 81.33%	Perf 3Y	-30.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	0.00%	Volatility	5.33% 4.63%	Perf 5Y	-
Dividend TTM	-	EV/Sales	147.67	EPS Y/Y TTM	45.49%	Oper. Margin	-4835.00%	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.07	Sales Y/Y TTM	-	Profit Margin	-4232.50%	RSI (14)	55.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.07	EPS Q/Q	-7.08%	SMA20	0.65%	Beta	1.27	Target Price	5.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	11.28%	Rel Volume	0.56	Prev Close	1.30
Employees	10	LT Debt/Eq	0.01	Earnings	May 15 AMC	SMA200	18.92%	Avg Volume	166.97K	Price	1.36
IPO	Aug 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% 7.47%	Trades		Volume	93,331	Change	4.62%

Jun-05-25 11:00PM	RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results (Insider Monkey)
May-16-25 09:42AM	Q1 2025 RenovoRx Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
03:15AM	RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ... (GuruFocus.com)
May-15-25 07:30PM	RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.71%
04:05PM	RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
08:30AM	Loading…
May-14-25 08:30AM	RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st (Business Wire)
May-06-25 08:30AM	U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP) Therapy Platform (Business Wire)
May-01-25 08:30AM	RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET (Business Wire)
Apr-29-25 08:30AM	Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRxs Ongoing Phase III TIGeR-PaC Clinical Trial (Business Wire)
Apr-16-25 08:30AM	RenovoRx Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community (Business Wire) +14.44%
Apr-04-25 08:30AM	RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th (Business Wire)
Apr-01-25 08:30AM	RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire)
Mar-28-25 08:00AM	RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting (Business Wire)
Mar-26-25 08:00AM	RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting (Business Wire)
Mar-20-25 08:00AM	RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET (Business Wire)
08:00AM	Loading…
Mar-19-25 08:00AM	RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 (Business Wire)
Feb-26-25 08:00AM	RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders (Business Wire)
Feb-13-25 08:00AM	RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery (Business Wire) -11.21%
Feb-11-25 07:00AM	RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
Feb-07-25 03:11AM	RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement (GuruFocus.com) -20.55%
Feb-06-25 08:49PM	RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
04:05PM	RenovoRx Announces Proposed Public Offering (Business Wire)
Jan-27-25 12:48PM	ASCO GI: RenovoRXs TAMP system reduces side effects in pancreatic cancer (Clinical Trials Arena)
08:00AM	RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 (Business Wire)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-08-25 08:00AM	RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 (Business Wire)
Dec-30-24 08:00AM	RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform (Business Wire) +6.92%
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-11-24 08:00AM	RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Dec-10-24 08:00AM	RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET (GlobeNewswire)
05:01AM	Loading…
Dec-06-24 05:01AM	RenovoRx begins commercialisation of RenovoCath device (Medical Device Network)
Dec-05-24 08:00AM	RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath Delivery System (GlobeNewswire) +15.97%
Nov-20-24 08:45AM	Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire) +7.21%
Nov-14-24 08:00AM	RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Sep-25-24 08:30AM	RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians (GlobeNewswire)
Sep-19-24 08:30AM	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire)
Aug-27-24 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York (GlobeNewswire)
Aug-14-24 12:13PM	RenovoRx continues drug-device combo Phase III trial in pancreatic cancer (Medical Device Network)
08:30AM	RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Aug-13-24 10:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 (InvestorPlace)
Jul-31-24 08:30AM	RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) -6.98%
Jul-08-24 08:30AM	RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) +6.61%
Jun-26-24 08:30AM	University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Jun-10-24 08:30AM	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships (GlobeNewswire)
May-30-24 08:30AM	RenovoRx CEO Issues Update Letter to Shareholders (Business Wire)
May-21-24 09:00AM	Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRxs TAMP Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery (Business Wire)
May-14-24 09:00AM	RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024 (Business Wire)
May-13-24 09:53AM	RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024 (InvestorPlace)
May-02-24 09:00AM	RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 (Business Wire)
Apr-18-24 08:30AM	RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement (Business Wire)
Apr-16-24 08:30AM	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Apr-15-24 08:00AM	RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 (Business Wire) -5.74%
Apr-08-24 01:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023 (InvestorPlace)
08:30AM	RenovoRx Announces $11.1 Million at Market Private Placement (Business Wire)
Apr-05-24 08:30AM	RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024 (Business Wire)
Mar-12-24 09:00AM	RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024 (Business Wire)
Mar-08-24 04:05PM	RenovoRx Highlights Key Leadership Promotions (Business Wire)
Feb-06-24 08:30AM	RenovoRx CEO Issues Letter to Shareholders (Business Wire)
Jan-29-24 08:30AM	RenovoRx Closes $6.1 Million Private Placement (Business Wire) +15.24%
Dec-21-23 08:30AM	RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer (Business Wire) +19.68%
Dec-19-23 08:30AM	RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire) -8.22%
Dec-13-23 08:31AM	RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform (Business Wire) +25.35%
Nov-16-23 08:35AM	RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D. (Business Wire) -15.82%
Nov-14-23 08:30AM	RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire) -28.34%
Oct-02-23 08:30AM	RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023 (Business Wire) -16.92%
Aug-17-23 08:30AM	RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire) +7.60%
Jul-31-23 08:30AM	RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference (Business Wire)
Jul-20-23 08:00AM	RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform (Business Wire)
Jun-29-23 11:42AM	RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform (News Direct) +9.38%
08:00AM	RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer (Business Wire)
Jun-20-23 08:30AM	RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board (Business Wire)
Jun-12-23 08:30AM	RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15 (Business Wire)
Jun-01-23 08:30AM	RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire) +13.44%
May-25-23 08:30AM	RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer (Business Wire)
May-24-23 08:30AM	RenovoRx to Present at the LD Micro Invitational XIII Conference (Business Wire) -8.42%
May-15-23 08:30AM	RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire) +10.95%
May-01-23 08:30AM	RenovoRx Sponsors Pancreatic Cancer Action Networks PurpleStride® Event (Business Wire)
Apr-28-23 08:30AM	RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023 (Business Wire)
Apr-27-23 08:30AM	RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors (Business Wire) +11.87%
Apr-14-23 08:30AM	RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida (Business Wire)
Apr-11-23 08:30AM	RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations (Business Wire)
Mar-30-23 12:20PM	RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) -13.59%
08:30AM	RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy (Business Wire)
Mar-22-23 09:00AM	RenovoRxs Principal Investigator of Phase III Clinical Trial Discusses Positive Interim Results on Patients with Locally Advanced Pancreatic Cancer on OncologyTube (News Direct)
Mar-08-23 12:26PM	RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care (Benzinga) +6.12%
08:30AM	RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer (Business Wire)
Mar-03-23 10:00AM	RenovoRX's Latest Innovative Technology Creates New Hope For Chemotherapy Patients (News Direct) +5.69%
Mar-02-23 08:30AM	RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone (Business Wire)
Mar-01-23 08:30AM	RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023 (Business Wire) +9.68%
Jan-25-23 08:30AM	RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023 (Business Wire)
Jan-18-23 12:31PM	RenovoRx Reports Initial Results From Targeted Treatment For Pancreatic Cancer (Benzinga) -7.59%
08:30AM	RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment (Business Wire)
Jan-11-23 10:43AM	Here's Why RenovoRx (NASDAQ:RNXT) Must Use Its Cash Wisely (Simply Wall St.) -5.68%
Jan-05-23 08:30AM	RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent (Business Wire)
Dec-15-22 08:30AM	RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium (Business Wire) +7.40%
Nov-17-22 08:30AM	RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers (Business Wire) -5.50%
Nov-14-22 08:30AM	RenovoRx Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-21-22 08:30AM	RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET (Business Wire) -7.45%
Oct-04-22 08:00AM	RenovoRx to Participate in Upcoming October 2022 Investor Conferences (Business Wire)
Sep-28-22 08:30AM	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer (Business Wire) +8.11%

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agah Ramtin	Chief Medical Officer	Jun 05 '25	Buy	1.40	21,000	29,400	734,460	Jun 09 06:03 AM
Marton Laurence	Director	May 02 '25	Option Exercise	0.15	20,480	3,072	66,164	May 06 04:10 PM
Agah Ramtin	Chief Medical Officer	Apr 15 '25	Buy	0.90	15,000	13,500	1,113,460	Apr 17 06:10 AM
Bagai Shaun	Chief Executive Officer	Apr 15 '25	Buy	0.91	7,500	6,821	320,040	Apr 16 06:08 AM
Agah Ramtin	Chief Medical Officer	Apr 11 '25	Buy	0.80	20,000	16,000	1,098,460	Apr 14 06:30 AM
Kocak Ron	VP Controller and PAO	Apr 10 '25	Buy	0.79	6,500	5,135	12,595	Apr 10 07:02 PM
Kocak Ron	VP Controller and PAO	Apr 09 '25	Buy	0.80	6,000	4,800	6,095	Apr 10 07:02 PM
Kocak Ron	VP Controller and PAO	Apr 08 '25	Buy	0.80	95	76	95	Apr 10 07:02 PM
Agah Ramtin	Chief Medical Officer	Apr 09 '25	Buy	0.81	30,000	24,399	1,078,460	Apr 10 04:30 PM
Bagai Shaun	Chief Executive Officer	Apr 09 '25	Buy	0.83	10,000	8,300	312,540	Apr 10 06:02 AM
Marton Laurence	Director	Apr 08 '25	Buy	0.85	12,050	10,218	45,684	Apr 09 09:30 PM
Agah Ramtin	Chief Medical Officer	Apr 08 '25	Buy	0.84	26,000	21,840	1,048,460	Apr 09 12:45 PM
Bagai Shaun	Chief Executive Officer	Apr 07 '25	Buy	0.83	10,000	8,300	302,540	Apr 08 11:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNXT

RenovoRx Inc

Upgrade your FINVIZ experience